Lisata Therapeutics Inc (LSTA)

[whirlybird]

A P3 SPA and fast track approved FDA study
for metastatic melanoma is a very, very big deal. An important question is how will NBS pay for this. A reasonable supposition is that the PreSERVE results due in about two months will be positive and that there will be a secondary offering afterwards. Maybe there will be another partnership (BAX for example) to fund this study. The P2 results for met. melanoma were almost unbelievable with more than a doubling in overall survival. Based upon faith that results that outstanding will get financed somehow or another, I believe that NBS will somehow come up with the estimated 25 million needed to fund the study. I still feel NBS is on its way to @15 later this year.